Zobrazeno 1 - 10
of 4 340
pro vyhledávání: '"S. Hin"'
Publikováno v:
Journal of Palestine Studies, 2004 Jan . 33(2), 185-190.
Externí odkaz:
https://www.jstor.org/stable/10.1525/jps.2004.33.2.185
Publikováno v:
Journal of Palestine Studies, 2004 Jan . 33(2), 177-185.
Externí odkaz:
https://www.jstor.org/stable/10.1525/jps.2004.33.2.177
Autor:
Kesztenbaum, Lionel
Publikováno v:
Population (English Edition, 2002-), 2022 Jan 01. 77(1), 156-157.
Externí odkaz:
https://www.jstor.org/stable/27185449
Autor:
Harper, Kyle
Publikováno v:
The Journal of Roman Studies, 2014 Jan 01. 104, 275-276.
Externí odkaz:
https://www.jstor.org/stable/43286903
Autor:
Kyle Harper
Publikováno v:
Journal of Roman Studies. 104:275-276
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a618d1985bc85d576e59dd6c9160e682
https://doi.org/10.1017/s0075435814000380
https://doi.org/10.1017/s0075435814000380
Publikováno v:
Proceedings of Singapore Healthcare, Vol 31 (2022)
Osimertinib is a third-generation thyroxine kinase inhibitor (TKI) used in treating advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. Osimertinib is used as a second line treatment for patient
Externí odkaz:
https://doaj.org/article/a3bb8b3e473b499e9ee4bde99f202de4
Autor:
Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu
Publikováno v:
Future Oncology. 18:1039-1054
MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4c5b96a113868d2d819fcd3ed9a4f3a
https://doi.org/10.2217/fon-2021-1406
https://doi.org/10.2217/fon-2021-1406
Publikováno v:
Materials Science and Engineering: A. 864:144533
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6ac968347502f2ac65e97a234159be5
https://doi.org/10.1016/j.msea.2022.144533
https://doi.org/10.1016/j.msea.2022.144533
Autor:
Egbert, F Smit, Christophe, Dooms, Jo, Raskin, Ernest, Nadal, Lye M, Tho, Xiuning, Le, Julien, Mazieres, How, S Hin, Masahire, Morise, Viola, W Zhu, Daniel, Tan, Kristina, H Holmberg, Barbara, Ellers-Lenz, Svenja, Adrian, Sabine, Brutlach, Karl M, Schumacher, Niki, Karachaliou, Yi-Long, Wu
Publikováno v:
Future oncology (London, England). 18(9)
Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::47a030a95679cd310cb1dc7f22888d9a
https://pubmed.ncbi.nlm.nih.gov/34918545
https://pubmed.ncbi.nlm.nih.gov/34918545
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.